SOURCE: AtCor Medical Holdings Ltd.

AtCor Medical Holdings Ltd.

October 08, 2012 10:26 ET

AtCor Medical Announces $3.2 Million Pharmaceutical Clinical Trial Contract

ITASCA, IL--(Marketwire - Oct 8, 2012) -  AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system, which measures central aortic pressures and arterial stiffness noninvasively, today announced that it has signed a contract to supply SphygmoCor® systems and clinical trial support services to a major pharmaceutical company. Systems will be placed at sites throughout Europe and North America. The value of the contract is approximately $3.2 million.

Duncan Ross, CEO of AtCor Medical, said, "We are delighted to have secured this significant contract. This, together with the $1.1 million pharmaceutical contract announced in August, represents a very good start to our financial year."

"This contract is with an existing client that we have worked with for many years," Ross said. "The non-invasive measurement of central blood pressure and arterial stiffness is particularly important for drug development, which requires accurate, insightful data to fully understand the efficacy of new drugs. It is encouraging that AtCor's gold standard technology, data management and support services are being validated through repeat business from the pharmaceutical sector."

About AtCor Medical 

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure and arterial stiffness noninvasively. The company's SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 2,900 SphygmoCor® systems are currently in use worldwide at major medical centers, research institutions, in physicians' offices and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 600 peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States and Europe. For further information, please visit our web site at